Brompheniramine


Concise Prescribing Info
Indications/Uses
Allergic conditions.
Dosage/Direction for Use
Adult: PO 4 mg 4-6 hrly.
Administration
May be taken with or without food. May be taken w/ food or milk to reduce GI discomfort.
Contraindications
Pregnancy (3rd trimester).
Special Precautions
Patient w/ glaucoma, prostatic hyperplasia, genitourinary obstruction, asthma, chronic bronchitis, thyroid dysfunction, CV disease (e.g. HTN, ischaemic heart disease). Childn. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness and sedation, if affected, do not drive or operate machinery.
Adverse Reactions
Excitability (esp in childn), drowsiness, sedation, angina pectoris, chest tightness, circulatory shock, extrasystoles, hypotension, palpitation, increased BP, tachycardia, anxiety, ataxia, chills, confusion, euphoria, fatigue, headache, hysteria, insomnia, irritability, nervousness, neuritis, paraesthesia, restlessness, seizure, tension, vertigo, diaphoresis, photosensitivity, rash, urticaria, abdominal cramps, anorexia, constipation, diarrhoea, epigastric distress, heartburn, nausea, vomiting, xerostomia, dysuria, early menstruation, urinary retention, agranulocytosis, haemolytic anaemia, thrombocytopenia, tremor, weakness, diplopia, mydriasis, blurred vision, acute labyrinthitis, tinnitus, polyuria, dry nose or throat, nasal congestion, bronchial secretions, wheezing.
Drug Interactions
May enhance the sedative effects of CNS depressants (e.g. barbiturates, anxiolytics, hypnotics, opioid analgesics, antipsychotics). Additive antimuscarinic effects w/ other antimuscarinic drugs (e.g. atropine, TCAs, MAOIs). May mask the warning signs of damage caused by ototoxic drugs (e.g. aminoglycosides).
ATC Classification
R06AB01 - brompheniramine ; Belongs to the class of substituted alkylamines used as systemic antihistamines.
Disclaimer: This information is independently developed by CIMS based on brompheniramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in